# US 2026/0098043 A1 · Polycyclic compound and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098043 A1
- Document ID: US20260098043A1
- Status: Published application
- Kind: A1
- Application number: 19/111,594
- Filed: 2023-09-13
- Published: 2026-04-09
- Earliest claimed: 2022-09-14
- Assignees: Hainan Simcere Zaiming Pharmeceutical Co., Ltd.
- Applicants: Hainan Simcere Zaiming Pharmeceutical Co., Ltd.
- Inventors: Jinghai JIN; Yuewen LI; Yu SHI; Wei ZHU; Zhengtao LI
- Web page: https://patentgrep.com/patent/US20260098043A1

## CPC

- C07D 495/14: Ortho-condensed systems
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61P 35/00: Antineoplastic agents
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07D 487/14: Ortho-condensed systems
- C07D 487/16: Peri-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D 498/08: Bridged systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

A compound represented by formula (I) CLM-L-PTM or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a use thereof, which are particularly suitable for preparing drugs for treating or preventing abnormal cell proliferation diseases.

## Claims

### Claim 1

A compound represented by formula (I) or a pharmaceutically acceptable salt thereof:
wherein,
CLM has the structure shown below:
“” is selected from a single bond and a double bond;
Z is selected from C(R3)2, NR3, and O;
ring B is selected from 5- to 6-membered heteroaromatic ring, 5- to 8-membered heterocyclic ring, benzene ring, and C5-C8 saturated or partially saturated carbon ring;
ring C is selected from 5- to 6-membered heteroaromatic ring, 5- to 8-membered heterocyclic ring, benzene ring, and C5-C8 saturated or partially saturated carbon ring;
R1, R2, and R5 are each independently selected from halogen, ═O, CN, NO2, —ORb, —N(Rb)2, —S(O)Rb, —SO2Rb, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, and 5- to 10-membered heteroaryl, wherein the 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with Ra;
each R3 is independently selected from H, halogen, ═O, CN, NO2, —ORb, —N(Rb)2, —S(O)Rb, —SO2Rb, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, and 5- to 10-membered heteroaryl, wherein the 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with Ra;
or R1 and R3, together with the atoms linked thereto, form C5-C8 saturated or partially saturated carbon ring, 5- to 6-membered heteroaromatic ring, or 5- to 8-membered heterocyclic ring, wherein the C5-C8 saturated or partially saturated carbon ring, 5- to 6-membered heteroaromatic ring, or 5- to 8-membered heterocyclic ring is optionally substituted with R5;
each R4 is independently selected from halogen, CN, NO2, OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, and 5- to 10-membered heteroaryl, wherein the OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with Ra;
each Ra is independently selected from halogen, CN, OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, and 4- to 8-membered heterocyclyl, wherein the 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, or 4- to 8-membered heterocyclyl is optionally substituted with Rc;
each Rb is independently selected from H, halogen, CN, OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, and 4- to 8-membered heterocyclyl, wherein the OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, or 4- to 8-membered heterocyclyl is optionally substituted with Rc;
each Rc is independently selected from halogen, CN, OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, and 4- to 8-membered heterocyclyl, wherein the OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, or 4- to 8-membered heterocyclyl is optionally substituted with Rd;
each Rd is independently selected from halogen, CN, OH, NH2, and C1-C6 alkyl;
n is independently selected from 0, 1, 2, 3, and 4;
m and p are independently selected from 0, 1, 2, 3, 4, 5, and 6;
L represents a linking unit of CLM and PTM;
PTM is selected from binding moieties of targeted proteins.

### Claim 2 (depends on 1)

The compound represented by formula (I) or the pharmaceutically acceptable salt thereof according to claim 1, wherein Z is selected from NR3 and O; or
wherein ring B is selected from 5- to 6-membered heteroaromatic ring, 5- to 6-membered heterocyclic ring, benzene ring, and C5-C6 saturated or partially saturated carbon ring; or
wherein ring C is selected from 5- to 6-membered heteroaromatic ring, 5- to 6-membered heterocyclic ring, benzene ring, and C5-C6 saturated or Partially saturated carbon ring.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The compound represented by formula (I) or the pharmaceutically acceptable salt thereof according to claim 1, wherein CLM has a structure represented by formula (II):
wherein X1 and X2 are independently selected from N and CH, wherein the CH is optionally substituted with R2; ring C, Z, R1, R2, R4, m, and n are as defined in claim 1.

### Claim 6 (depends on 1)

The compound represented by formula (I) or the pharmaceutically acceptable salt thereof according to claim 1, wherein
CLM is selected from structures represented by formulas (II-1a) and (II-1b):
wherein X1 and X2 are independently selected from N and CH, wherein the CH is optionally substituted with R2; Y1, Y2, Y3, and Y4 are independently selected from N and CH, wherein the CH is optionally substituted with R1; “” is selected from a single bond and a double bond; Q1, Q2, and Q3 are independently selected from O, S, NH, CH2, N, and CH, wherein the NH, CH2, or CH is optionally substituted with R1; Z, R1, R2, R4, and n are as defined in claim 1.

### Claim 7 (depends on 1)

The compound represented by formula (I) or the pharmaceutically acceptable salt thereof according to claim 1, wherein R1 and R2 are independently selected from halogen, CN, OH, NH2, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, and C3-C10 cycloalkyl, wherein the OH, NH2, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, or C3-C10 cycloalkyl is optionally substituted with Ra; or
wherein R5 is independently selected from halogen, ═O, CN, OH, NH2, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, and C3-C10 cycloalkyl, wherein the OH, NH2, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, or C3-C10 cycloalkyl is optionally substituted with Ra; or
wherein R3 is independently selected from H, halogen, CN, OH, NH2, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, and C3-C10 cycloalkyl, wherein the OH, NH2, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, or C3-C10 cycloalkyl is optionally substituted with Ra; or
wherein R1 and R3, together with the atoms linked thereto, form 5-, 6-, 7-, or 8-membered heterocyclic ring, wherein the 5-, 6-, 7-, or 8-membered heterocyclic ring is optionally substituted with R5; or
wherein each R4 is independently selected from halogen, CN, OH, NH2, and C1-C6 alkyl, wherein the OH, NH2, or C1-C6 alkyl is optionally substituted with Ra; or
wherein each Ra is independently selected from halogen, CN, OH, NH2, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, and 4- to 8-membered heterocyclyl, wherein the C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, or 4- to 8-membered heterocyclyl is optionally substituted with Rc; or
wherein m and P are independently selected from 0, 1, 2, 3, and 4; or
wherein n is selected from 0 and 1.

### Claim at position 8

-14. (canceled)

### Claim 15 (depends on 1)

The compound represented by formula (I) or the pharmaceutically acceptable salt thereof according to claim 1, wherein L is selected from
wherein M1 and M2 are independently selected from bond, —NR20—, —C(O)—, —C(O)O—, —SO2—, —S(O)—, —O—, —S—, —C(═S)—, —C(O)NR20—, —NR20C(O)O—, —NR20S(O)2—, 2- to 10-membered heteroalkylene, C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, C3-C10 cycloalkylene, 4- to 9-membered heterocyclylene, C6-C10 arylene, and 5- to 10-membered heteroarylene, wherein the 2- to 10-membered heteroalkylene, C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, C3-C10 cycloalkylene, 4- to 9-membered heterocyclylene, C6-C10 arylene, or 5- to 10-membered heteroarylene is optionally substituted with R21;
R10, R11, R12, R13, R14, R15, and R16 are independently selected from bond, —(O—CH2CH2)k—, —C(O)—, —C(O)O—, —SO2—, —S(O)—, —O—, —S—, —C(S)—, —C(═NR20)—, —C(O)NR20—, —NR20—, —NR20C(O)O—, —NR20S(O)2—, —P(O)R20—, —P(O)(OR20)O—, —P(O)(OR20)—,
2- to 10-membered heteroalkylene, C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, C3-C10 cycloalkylene, 4- to 9-membered heterocyclylene, C6-C10 arylene, and 5- to 10-membered heteroarylene, wherein the 2- to 10-membered heteroalkylene, C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, C3-C10 cycloalkylene, 4- to 9-membered heterocyclylene, C6-C10 arylene, or 5- to 10-membered heteroarylene is optionally substituted with R21;
k is independently selected from 1, 2, 3, 4, 5, and 6;
R20 is selected from H, halogen, CN, OH, NH2, C1-C10 alkyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, and 5- to 10-membered heteroaryl, wherein the OH, NH2, C1-C10 alkyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with Rf;
R21 is selected from halogen, CN, OH, NH2, C1-C10 alkyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, and 5- to 10-membered heteroaryl, wherein the OH, NH2, C1-C10 alkyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with Rf;
each Rf is independently selected from halogen, CN, OH, NH2, and C1-C6 alkyl.

### Claim 16 (depends on 15)

The compound represented by formula (I) or the pharmaceutically acceptable salt thereof according to claim 15, wherein L is selected from
wherein M1, M2, R10, R11, R12, R13, and R14 are as defined in claim 15; or
wherein L is selected from
wherein R10, R11, R12, R13, and R14 are independently selected from bond, —(O—CH2CH2)k—, —C(O)—, —C(O)O—, —O—, —C(O)NR20—, —NR20—, —NR20C(O)O—, —NR20S(O)2—, C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, 4- to 9-membered heterocyclylene, C6-C10 arylene, and 5- to 10-membered heteroarylene, wherein the C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, 4- to 9-membered heterocyclylene, C6-C10 arylene, or 5- to 10-membered heteroarylene is optionally substituted with R21; M1, M2, R20, R21, and k are as defined in claim 15; or
wherein L is selected from
wherein M1, M2, R10, R11, and R12 are as defined in claim 15.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 15)

The compound represented by formula (I) or the pharmaceutically acceptable salt thereof according to claim 15, wherein M1 and M2 are independently selected from bond, —NR20—, —C(O)—, —C(O)O—, —O—, —S—, —C(O)NR20—, —NR20C(O)O—, —NR20S(O)2—, 2- to 10-membered heteroalkylene, C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, C3-C10 cycloalkylene, 4- to 9-membered heterocyclylene, C6-C10 arylene, and 5- to 10-membered heteroarylene, wherein the 2- to 10-membered heteroalkylene, C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, C3-C10 cycloalkylene, 4- to 9-membered heterocyclylene, C6-C10 arylene, or 5- to 10-membered heteroarylene is optionally substituted with R21, wherein R20 and R21 are as defined in claim 15; or
wherein R10, R11, R12, R13, R14, R15, and R16 are independently selected from bond, —(O—CH2CH2)k—, —C(O)—, —C(O)O—, —SO2—, —S(O)—, —O—, —S—, —C(O)NR20—, —NR20—, —NR20C(O)O—, —NR20S(O)2—, 2- to 10-membered heteroalkylene, C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, C3-C10 cycloalkylene, 4- to 9-membered heterocyclylene, C6-C10 arylene, and 5- to 10-membered heteroarylene, wherein the 2- to 10-membered heteroalkylene, C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, C3-C10 cycloalkylene, 4- to 9-membered heterocyclylene, C6-C10 arylene, or 5- to 10-membered heteroarylene is optionally substituted with R21, wherein k, R20, and R21 are as defined in claim 15.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The compound represented by formula (I) or the pharmaceutically acceptable salt thereof according to claim 1, wherein PTM is selected from binding moieties of the following targeted proteins: ALK, AR, BET1, BRAF, BRCA2, BRD4, BRD9, BTK, BRM, CBL, CCNE1, CCNE2, CCR4, CCR7, CCR9, CD47, CLDN18, CYP, DDR1, DMPK, EGFR, ERBB2, ERBB3, ERBB4, FGFR1, FGFR2, FGFR3, FGFR4, GSPT1, JAK1, JAK3, KIF18A, KRAS, LCK, MET, NTRK1, NTRK2, NTRK3, PCSK9, PKMYT1, PARP7, PARP14, RAD51, RBM10, RET, RORA, STAT3, SOS1, TYK2, USP1, and USP14.

### Claim 22 (depends on 1)

The compound represented by formula (I) or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound represented by formula (I) or the pharmaceutically acceptable salt is selected from:

### Claim 23 (depends on 1)

A pharmaceutical composition, comprising the compound represented by formula (I) or the pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable excipient.

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 1)

A method for treating an abnormal cell proliferation disease in a mammal, comprising administering to a mammal in need of the treatment a therapeutically effective amount of the compound represented by formula (I) or the pharmaceutically acceptable salt thereof according to claim 1.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the abnormal cell proliferation disease is cancer.

### Claim 28

A compound represented by formula (III) or a pharmaceutically acceptable salt thereof:
wherein X1 and X2 are independently selected from N and CH, wherein the CH is optionally substituted with R2;
Z is selected from C(R3)2, NR3, and O;
R1, R2, and R5 are each independently selected from halogen, ═O, CN, NO2, —ORb, —N(Rb)2, —S(O)Rb, —SO2Rb, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, and 5- to 10-membered heteroaryl, wherein the 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with Ra;
each R3 is independently selected from H, halogen, ═O, CN, NO2, —ORb, —N(Rb)2, —S(O)Rb, —SO2Rb, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, and 5- to 10-membered heteroaryl, wherein the 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with Ra;
or R1 and R3, together with the atoms linked thereto, form C5-C8 saturated or partially saturated carbon ring, 5- to 6-membered heteroaromatic ring, or 5- to 8-membered heterocyclic ring, wherein the C5-C8 saturated or partially saturated carbon ring, 5- to 6-membered heteroaromatic ring, or 5- to 8-membered heterocyclic ring is optionally substituted with R5;
each R4 is independently selected from halogen, CN, NO2, OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, and 5- to 10-membered heteroaryl, wherein the OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with Ra;
each Ra is independently selected from halogen, CN, OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, and 4- to 8-membered heterocyclyl, wherein the 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, or 4- to 8-membered heterocyclyl is optionally substituted with Rc;
each Rb is independently selected from H, halogen, CN, OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, and 4- to 8-membered heterocyclyl, wherein the OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, or 4- to 8-membered heterocyclyl is optionally substituted with Rc;
each Rc is independently selected from halogen, CN, OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, and 4- to 8-membered heterocyclyl, wherein the OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, or 4- to 8-membered heterocyclyl is optionally substituted with Rd;
each Rd is independently selected from halogen, CN, OH, NH2, and C1-C6 alkyl;
n is independently selected from 0, 1, 2, 3, and 4;
m and P are independently selected from 0, 1, 2, 3, 4, 5, and 6;
L represents a linking unit;
ring C is selected from 5- to 6-membered heteroaromatic ring and benzene ring;
provided that the following compounds or pharmaceutically acceptable salts thereof are excluded:

### Claim 29 (depends on 28)

The compound represented by formula (III) or the pharmaceutically acceptable salt thereof according to claim 28, wherein the compound represented by formula (III) or the pharmaceutically acceptable salt thereof is selected from a compound represented by formula (III-1a) or formula (III-1b) or a pharmaceutically acceptable salt thereof:
wherein X1 and X2 are independently selected from N and CH, wherein the CH is optionally substituted with R2; Y1, Y2, Y3, and Y4 are independently selected from N and CH, wherein the CH is optionally substituted with R1; “” is selected from a double bond; Q1, Q2, and Q3 are independently selected from O, S, NH, CH2, N, and CH, wherein the NH, CH2, or CH is optionally substituted with R1; Z, R1, R2, R4, n, and L are as defined in claim 28;
provided that the following compounds or pharmaceutically acceptable salts thereof are excluded:

### Claim 30

A compound represented by formula (IV) or a pharmaceutically acceptable salt thereof:
wherein X1 and X2 are independently selected from N and CH, wherein the CH is optionally substituted with R2;
Z is selected from C(R3)2, NR3, and O;
R1, R2, and R5 are each independently selected from halogen, ═O, CN, NO2, —ORb, —N(Rb)2, —S(O)Rb, —SO2Rb, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, and 5- to 10-membered heteroaryl, wherein the 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with Ra;
each R3 is independently selected from H, halogen, ═O, CN, NO2, —ORb, —N(Rb)2, —S(O)Rb, —SO2Rb, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, and 5- to 10-membered heteroaryl, wherein the 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with Ra;
or R1 and R3, together with the atoms linked thereto, form C5-C8 saturated or Partially saturated carbon ring, 5- to 6-membered heteroaromatic ring, or 5- to 8-membered heterocyclic ring, wherein the C5-C8 saturated or partially saturated carbon ring, 5- to 6-membered heteroaromatic ring, or 5- to 8-membered heterocyclic ring is optionally substituted with R5;
each R4 is independently selected from halogen, CN, NO2, OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, and 5- to 10-membered heteroaryl, wherein the OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, 4- to 8-membered heterocyclyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with Ra;
each Ra is independently selected from halogen, CN, OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, and 4- to 8-membered heterocyclyl, wherein the 2- to 10-membered heteroalkyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, or 4- to 8-membered heterocyclyl is optionally substituted with Rc;
each Rb is independently selected from H, halogen, CN, OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, and 4- to 8-membered heterocyclyl, wherein the OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, or 4- to 8-membered heterocyclyl is optionally substituted with Rc;
each Rc is independently selected from halogen, CN, OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, and 4- to 8-membered heterocyclyl, wherein the OH, NH2, 2- to 10-membered heteroalkyl, C1-C10 alkyl, C3-C10 cycloalkyl, or 4- to 8-membered heterocyclyl is optionally substituted with Rd;
each Rd is independently selected from halogen, CN, OH, NH2, and C1-C6 alkyl;
n is independently selected from 0, 1, 2, 3, and 4;
m and P are independently selected from 0, 1, 2, 3, 4, 5, and 6;
ring C is selected from 5- to 6-membered heteroaromatic ring and benzene ring;
provided that the following compounds or pharmaceutically acceptable salts thereof are excluded:

### Claim 31 (depends on 30)

The compound represented by formula (IV) or the pharmaceutically acceptable salt thereof according to claim 30, wherein the compound represented by formula (IV) or the pharmaceutically acceptable salt thereof is selected from a compound represented by formula (IV-1a) or formula (IV-1 b) or a pharmaceutically acceptable salt thereof:
wherein X1 and X2 are independently selected from N and CH, wherein the CH is optionally substituted with R2; Y1, Y2, Y3, and Y4 are independently selected from N and CH, wherein the CH is optionally substituted with R1; “” is selected from a double bond; Q1, Q2, and Q3 are independently selected from O, S, NH, CH2, N, and CH, wherein the NH, CH2, or CH is optionally substituted with R1; Z, R1, R2, R4, and n are as defined in claim 30;
provided that the following compounds or pharmaceutically acceptable salts thereof are excluded:

### Claim 32

(canceled)

### Claim 33 (depends on 30)

The compound represented by the formula (IV) or a pharmaceutically acceptable salt thereof according to claim 30, selected from the following compounds or pharmaceutically acceptable salts thereof:

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36 (depends on 30)

A method for treating an abnormal cell proliferation disease in a mammal, comprising administering to a mammal in need of the treatment a therapeutically effective amount of the compound represented by formula (IV) or the pharmaceutically acceptable salt thereof according to claim 30.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the abnormal cell proliferation disease is cancer.